Guggenheim raised the firm’s price target on Merck to $123 from $116 and keeps a Buy rating on the shares after updating the firm’s model following the "impressive results" for both sotatercept and MK-0616 shared at ACC earlier this week. Based on the STELLAR results and a preliminary check with key opinion leaders who called the data "amazing," "unbelievable" and "transformational," the firm has increased its sotatercept forecasts and now estimates peak sales of $7.2B in 2031 versus the $4.7B it has previously forecast.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Opko Health Surges as Merck Considers Deal
- Opko Health enters exclusive worldwide license agreement with Merck
- Sotatercept data supports bullish view of Merck cardio franchise, says Jefferies
- Merck cardiovascular franchise set for ‘resurgence,’ says Mizuho